Streamex
Develops commodity-tokenization infrastructure alongside the PURE EP electrophysiology platform.
Something off on this page? Send us feedback.
Profile
Develops a blockchain-based platform for commodity real-world-asset tokenization and exchange alongside the legacy PURE EP electrophysiology business. The RWA platform was development-stage and had no revenue at the latest year-end.
Combines a development-stage commodity real-world-asset platform, acquired through Streamex Exchange, with BioSig's inherited PURE EP biomedical business. Streamex Exchange had developed digital tools for commodity trading and finance in Vancouver; the issuer later adopted the Streamex name and STEX ticker.
The blockchain-based platform is designed for compliant tokenization and exchange, and GLDY launched after the reporting period with subscriptions beginning thereafter. PURE EP remains focused on advanced signal acquisition and processing for electrophysiology. Future platform revenue depends on platform maturity, regulatory developments, market conditions, adoption and issuance volumes, and monetizing GLDY and other tokenized products through fees.
Company facts
Key statistics
Year to date −75.3% · Average volume (30d) 882.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Nov 25, 2025 | Needham | Target | $12 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | −$0.02 | −$0.08 | −300.0% | $300.0K | $300.0K | 0.0% | −13.79% |
| May 18, 2026Q1 FY26 | −$0.05 | −$0.27 | −440.0% | $1.0M | — | — | +20.17% |
| Mar 31, 2026Q4 FY25 | −$0.03 | −$0.03 | 0.0% | $50.0K | — | — | −1.77% |
| Nov 14, 2025Q3 FY25 | −$0.03 | −$0.47 | −1,466.7% | — | — | — | −3.62% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $146.0K | |
| Gross profit | $0 | $0 | −$1.5M | $2.0M | −$1.5M | −$1.3M | |
| Operating income | −$3.0M | −$20.4M | −$6.1M | −$41.6M | −$35.7M | −$15.2M | |
| Net income | −$2.8M | −$20.4M | −$15.6M | −$424.0M | −$46.7M | −$14.6M | |
| Diluted EPS | −$0.14 | −$0.74 | −$0.47 | −$8.84 | −$0.97 | −$0.08 | |
| Gross margin | — | — | — | — | — | -907.5% | |
| Operating margin | — | — | — | — | — | -10,384.2% |
Fiscal years (4-quarter sums)FY24 $40.0K · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $20.3M · Total debt $800.0K · Total assets $159.6M · Shareholders' equity $145.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 104.17M · Float 75.48M · 72.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Morgan Lee Lekstrom | 20.71M | 13.99% | 13D | Nov 10, 2025 |
| Avanico Limited | 17.37M | 12.02% | 13G | Sep 15, 2025 |
| Mitchell Young Williams · director, officer: Chief Investment Officer | 3.01M | 2.89% | Form 4 | Jun 2, 2026 |
| Giustra Frank · 10 percent owner | 1.28M | 1.23% | Form 4 | Feb 4, 2026 |
| Karl Henry Michael McPhie · director, officer: CEO | 969.4K | 0.93% | Form 4 | Apr 17, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 12, 2026 | Morgan Lee Lekstrom | director, officer: Interim Executive Chairman | +50,000 | $0.9950 |
| Jun 1, 2026 | Mitchell Young Williams | director, officer: Chief Investment Officer | −23,810 | $1.05 |
| May 28, 2026 | Morgan Lee Lekstrom | director, officer: Interim Executive Chairman | +34,000 | $1.47 |
| Jan 23, 2026 | Morgan Lee Lekstrom | director, officer: Interim Executive Chairman | +88,000 | $3.13 |
| May 21, 2026 | Anthony Mark Marciano | director | +17,745 | $1.13 |
Peers
- WisdomTree
Tokenized physical-gold issuance and spending infrastructure
- Figure
Blockchain-native RWA issuance, funding, and secondary markets
- Johnson & Johnson
3D electroanatomical mapping for catheter ablation
- Abbott
EP mapping platform for RF and pulsed-field ablation
- Circle
Tokenized-fund issuance and onchain collateral infrastructure
- Boston Scientific
Integrated EP mapping and navigation for RF and PFA
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Streamex | $0.7718 | +0.42% | $80.4M | — | 11.0 | 550.7 | — |
| WisdomTree | $24.33 | −0.45% | $3.74B | 47.0 | 20.3 | 6.1 | +57.3% |
| Figure | $36.01 | −0.06% | $6.58B | 47.4 | 28.6 | 9.2 | — |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Circle | $86.80 | −0.38% | $23.29B | 46.4 | — | 8.0 | +6.6% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Median | 41.3 | 20.3 | 6.4 | +7.5% |